BioCentury
ARTICLE | Clinical News

HA-Irinotecan: Phase II started

June 30, 2014 7:00 AM UTC

Alchemia said investigators began the Australian Phase II CHIME trial to evaluate HA-Irinotecan as part of FOLFIRI chemotherapy plus Erbitux cetuximab in about 50 patients with mCRC. HA-Irinotecan is in Phase III testing to treat mCRC. Alchemia and the Merck Serono S.A. unit of Merck KGaA (Xetra:MRK, Darmstadt, Germany) are supporting the trial. ...